Antibody-Drug Conjugate Demonstrates High Efficacy as First-Line Therapy in Aggressive Rare Hematologic Cancer
An emerging hope for patients battling blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive cancer of the blood, ...
